503A patient-specific compounding continues under narrower exceptions
ongoing monitoring is key
Understanding these differences can inform decisions about which medication might be most appropriate for individuals interested in potential alcohol-related benefits
GLP-1 Medications with a simple generic name of "semaglutide", "liraglutide", "tirzepatide", "dulaglutide", "exenatide", "exenatide microspheres", or "insulin degludec/liraglutide" and at least one of: A pharmaceutical class of "ANTI-OBESITY GLUCAGON-LIKE PEPTIDE-1 RECEP AGONIST" or "ANTIHYPERGLYCEMIC - INCRETIN MIMETICS COMBINATION" A pharmaceutical class that contains "GLP-1" A pharmaceutical subclass that contains the text "GLP-1"
Animal and clinical studies have shown that GLP-1RAs ameliorate liver inflammation and lower the risk of NAFLD and NASH developing into liver cancer
Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with type 2 diabetes and obesity